Local Coverage Determination (LCD) MoPath: Genetic Assay for Refractory Depression (DL35443) Released by CGS Medicare

On October 30, 2014, Assurex Health announced that Medicare had issued a Local Coverage Determination (LCD) that will provide coverage nationwide under Medicare Part B for GeneSight Psychotropic, a genetic test to guide medication decisions for depression. Coverage under the LCDs is limited to testing requested by psychiatrists. The test will be covered with no out-of-pocket cost to Medicare Part B beneficiaries. The test will be covered by Medicare fee-for-service and commercial Medicare Advantage plans. This document is the LCD issued by the Medicare contractor that will be handling all claims for the test . . .